Tuesday, August 18, 2026
ExploreSearch
Finance Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,812
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,812 facts checked against source5,219 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
SEC filingGlobeNewswire· May 14, 2026

LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update

View original at globenewswire.com
LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update BOCA RATON, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The continued growth of Liora Technologies Europe further strengthens LIXTE's ability to accelerate innovative cancer therapies, including proton therapy through the LIGHT System

    60% confidence

  • Following a recent study confirming the favorable safety profile of LB-100 in combination with GSK's dostarlimab, LIXTE has expanded its ovarian cancer trial

    60% confidence

  • Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer

    60% confidence

  • LB-100 is well-tolerated in cancer patients at doses associated with anti-cancer activity

    60% confidence

  • LIXTE is evaluating opportunities to expand strategically and grow its team through pursuit of complementary oncology assets to enhance the pipeline

    60% confidence

  • Liora's LiGHT System is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy

    60% confidence

  • LB-100 has consistently shown synergy with today's chemotherapy and immunotherapy approaches for the treatment of cancer

    60% confidence

  • A genetically acquired reduction in PP2A activity may increase responsiveness to immune checkpoint blockade in Ovarian Clear Cell Carcinoma, particularly in tumors harboring somatic PPP2R1A mutations resulting in loss of PP2A function

    60% confidence

Cited in these Via News reports